CMS advised and represented the shareholders in SIRION BIOTECH on the deal.
Listed US company PerkinElmer, Inc. has acquired SIRION BIOTECH, a leading global provider of viral vector-based technologies for cell and gene therapies. Sirion has established a strong portfolio of licensed vector technologies leveraged by over a dozen major pharmaceutical and biotech players researching more than 25 diseases and conditions. As part of the transaction, shareholders including High-Tech Gründerfonds (HTGF), Creathor Venture, KfW and Bayern Kapital sold their stakes in the firm, which is based in Martinsried near Munich. The shareholders had held an equity interest in SIRION since 2007 resulting from several venture capital rounds of financing.
CMS Germany’s team consisted of Stefan-Ulrich Müller (Picture), Lead Partner, Munich, Dr Michael Wangemann, Lead Partner, Munich, Dr Tilman Weichert, Partner, Munich, Viktoria Barthel, Associate, Munich, Sebastian Hummel, Associate, Munich, all Corporate/M&A, Venture Capital, Jörg Schrade, Partner, Munich, Tax, Stefan Lüft, Partner, Munich, Annika Lindemann, Senior Associate, Munich, both Intellectual Property, Dr Benedikt Forschner, Counsel, Munich, Labor, Employment & Pensions, Dr Markus Kaulartz, Counsel, Munich, TMC, Stefan Lehr, Partner, Frankfurt/Main, Competition & EU and Barbara Bayer, Counsel, Frankfurt/Main, Banking & Finance.
Involved fees earner: Viktoria Barthel – CMS Hasche Sigle; Barbara Bayer – CMS Hasche Sigle; Benedikt Forschner – CMS Hasche Sigle; Sebastian Hummel – CMS Hasche Sigle; Markus Kaulartz – CMS Hasche Sigle; Annika Lindemann – CMS Hasche Sigle; Stefan Lüft – CMS Hasche Sigle; Stefan-Ulrich Müller – CMS Hasche Sigle; Jörg Schrade – CMS Hasche Sigle; Michael Wangemann – CMS Hasche Sigle; Tilman Weichert – CMS Hasche Sigle; Stefan Lehr – CMS von Erlach Poncet AG;
Clients: Sirion Biotech GmbH ;